Repertoire Genesis Inc.

  • Chairman & CEO:
    Ryuji Suzuki
  • President & COO:
    Masuo Ichikawa



Innovating diagnostic and therapeutic development using next-generation immune diversity analysis

Repertoire Genesis Inc. provides Next-Gen T cell receptor (TCR)/B cell receptor (BCR) repertoire analysis that is based on unbiased gene amplification technology and bioinformatics. This analysis is quantitatively superior to conventional methods and can be used for a wide variety of applications, e.g., detection of malignant lymphoma and leukemia, identification of antigen-specific TCR/BCR in infections or cancer, and evaluation of the efficacy of anti-cancer drugs such as immune checkpoint blockers and cancer immune therapy. The platform is also expected to contribute to the efficient development of novel therapeutic agents such as TCR gene therapy, CAR-T cell therapy, and antibody drugs.



Ryuji Suzuki (former Shionogi employee) developed bioinformatics software for fast and accurate repertoire analysis on immunity cell receptors (TCR / BCR) with his original unbiased gene amplification technology.


Repertoire Genesis has a unique technology to analyze immune repertoire accurately and comprehensively from both antigen and antibody factors. The company has dramatically improved the efficiency of development of therapeutic drugs and diagnostic agents for the immune system by in-depth monitoring of immune response in-vivo.
Their analysis services are being used at numerous domestic and overseas research institutes and pharmaceutical companies including The University of Tokyo School of Medicine Hospital and The University of California San Diego. The company strives to further improve the accuracy of analysis through collaborative research.

UTEC’s value add

UTEC used its know-how of fostering of venture companies to play the role of a founding investor in addition to the investment. Furthermore, UTEC supported infrastructure development of Repertoire Genesis to accelerate the commercialization of technology after incorporation.
  • Unbiased next-gen T cell receptor (TCR)/ B cell receptor (BCR) repertoire analysis

  • Somatic mutation and neoantigen analysis